师资队伍


扫描此二维码分享

当前位置: 首页 > 师资队伍 > 正文

程魁

发布时间:2017年10月17日 浏览次数:

姓名:程魁

职称:教授,博士生导师

联系邮箱:chengk@smu.edu.cn

联系电话:020-61647192


学习经历:

2008.9-2011.6 南京大学,生物学,博士

2009.10-2011.5 美国科罗拉多大学与南京大学联合培养,化学生物学


工作经历:

2016.2-今 南方医科大学,教授

2014.10-2016.1 清华大学,助理研究员

2011.7-2014.9 科罗拉多大学,博士后


研究方向:

1. 抗炎/肿瘤免疫类新药发现;

2. 合成药物化学;

3. 分子探针的设计及细胞信号通路研究。


主要获奖情况:

1. 国家重大人才工程青年学者(2020);

2. 广东省“珠江学者”青年拔尖人才(2018);

3. 广东省药物化学“青年珠江学者” (2016);

4. 教育部自然科学奖二等奖(第5完成人) (2009);

5. 湖北省优秀硕士学位论文 (2007)。


主要科研课题:

1. 国家自然科学基金面上项目,新型高选择性TLR2激活剂的发现、优化和抗肿瘤免疫机制研究(82073689),2021.01-2024.12,主持

2. 南方医科大学杰青培育计划(G620310203),2020.07-2023.06,主持。

3. 广东省自然科学基金面上项目,靶向TLR1/2的咪唑桥连类衍生物:设计、合成和分子机制研究(2020A151501518),2019.10-2022.9,主持。

4. 广州市科技计划项目,新型靶向TLR2小分子激活剂的发现及其肿瘤免疫机制研究(2020A151501518),2019.04-2022.03, 主持。

5. 国家自然科学基金面上项目,新型抗动脉粥样硬化TLR3高选择性抑制剂的结构优化及作用机制研究 (81773558),2018.01-2021.12, 主持。

6. 广东省自然科学基金研究团队项目,HIV潜伏激活的分子机制与新型靶向性潜伏激活剂的研究(2018B030312010),2018.05-2023.04, 主持子课题。

7. 广东省青年珠江学者项目,珠江学者配套科研经费 (C1034077),2016.10-2019.9,主持。

8. 南方医科大学高层次人才引进科研项目 (C1033269),2016.3-2019.2,主持。


承担课程:

《药物化学》、《有机化学》


代表性论文:

1. Zheng, Y.J.; Nandakumar, K. S.; Cheng, K.*; “Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches”, J. Med. Chem. 2021, 64, 9577-9591. (IF 7.44, 药学小类I区). doi:10.1021/acs.jmedchem.0c02054.

2. Chen, Z.P.; Zhang, L.; Yang, J.J.; Zheng, L.; Hu, F.J.; Duan, S.; Nandakumar, K. S.; Liu, S.W.; Yin, H. Cheng, K.*; "Design, Synthesis and Structure-Activity Relationship of N-aryl-N'-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy", J. Med. Chem. 2021, 64, 7371-7389. (IF 7.44, 药学小类I区) doi:10.1021/acs.jmedchem.0c02266.

3. Duan, S.; Xu, X.; Wang, J.; Huang, L.; Peng, J.; Yu, T.; Zhou, Y.; Cheng, K.*; Liu, S.W.* “TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4+ T Cells”, J. Virol. 2021, 95, e0081621. (IF 5.10, 药学2区,病毒学顶刊) doi.org/10.1128/JVI.00816-21.

4. Yang, J.; Hu, F.; Guo, C.J.; Liang, Y.Q.; Song, H.; Cheng, K.*; " Discovery of isoliquiritigenin analogues that reverse acute hepatitis by inhibiting macrophage polarization”, Bioorg. Chem. 2021, 114, 105043. (IF 5.27, 药学小类I区) doi:10.1016/j.bioorg.2021.105043

5. Liang, Y.Q.; Nandakumar, K. S; Cheng, K.* “Design and pharmaceutical applications of proteolysis-targeting chimeric molecules” Biochem. Pharmacol. 2020, 182, 114211. (IF 5.85, 药学小类I区) doi: 10.1016/j.bcp.2020.114211.

6. Zheng, L.; Zhang, L.; Huang, J.; Nandakumar, K.S.; Liu, S.W.*; Cheng, K.* “Potential treatment methods targeting 2019-nCoV infection”. Eur. J. Med. Chem. 2020, 205, 112687. (IF 6.51, 药学小类I区) doi: 10.1016/j.ejmech.2020.112687

7. Chen, Y.L.; Cheng. K.* “Advances of biological-camouflaged nanoparticles delivery system”. Nano Res. 2020, 13, 2617-2624. doi: 10.1007/s12274-020-2931-5. (IF 8.89, 大类1区)

8. Wen, K.M.; Fang, X.C.; Yang, J.L. Yao, Y.F.; Nandakumar, K. S.; Salem, M. L.; Cheng. K.* “Recent Research on Flavonoids and their Biomedical applications”. Curr. Med. Chem. 2020, 27, 1-25. doi: 10.2174/0929867327666200713184138. (IF 4.53, 药学3区)

9. Tang, X.S.; Yang, J.; Wang, W.Q.; Zeng, Y.N.; Li, J.P.; Lin S.S.; Nandakumar, K.S.; Cheng, K.* “Immunotherapy for Treating Methamphetamine, Heroin and Cocaine Use Disorders”. Drug Discov. Today 2020, 25, 610-619. doi: 10.1016/j.drudis.2019.07.009. (IF 7.85, 小类I区)

10. Lin, Y.; Fan, J.*; Ruan, L.; Bi, J.; Yan, Y.; Wang, T.; Gao, H. *; Yao X.S.; Cheng, K.*; Zhang, W.G.* “Semi-preparative separation of dihydromyricetin enantiomers by supercritical fluid chromatography and determination of anti-inflammatory activities”. J. Chromatogr. A. 2019, 1606 , 460386 (IF 4.75, 小类I区)

11. Yang, J.; Tang, X.S.; Nandakumar, K.S.; Cheng, K.* “Autophagy induced by STING, an unnoticed and primordial function of cGAS”. Cell. Mol. Immunol. 2019, 16, 683-684. doi: 10.1038/s41423-019-0240-2. (IF 11.53, 大类1区)

12. Bi, J.J.; Wang, W.Q.; Du, J.X.; Chen, K.; Cheng, K.* “Structure-activity relationship study and biological evaluation of SAC-Garlic acid conjugates as novel anti-inflammatory agents”. Eur. J. Med. Chem. 2019, 179, 233-245. (IF 6.51, 药学小类I区) doi: 10.1016/j.ejmech.2019.06.059

13. Cen, X.; Zhu, G.Z.; Yang, J.J.; Guo, J.Y.; Jin, J.B.; Nandakumar, K.S.; Yang, W.; Yin, H.; Liu, S.W.; Cheng, K.* “TLR1/2 Specific Small-molecule Agonist Suppresses Leukemia cancer cell growth by stimulating Cytotoxic T lymphocytes”. Adv. Sci. 2019, 6, 1802042. (IF 16.80, 大类1区)doi: 10.1002/advs.201802042

14. Chen, Z.; Cen, X.; Yang, J.; Lin, Z.; Liu, M.; Cheng, K.* “Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors”. Eur. J. Med. Chem. 2019, 169, 42-52. (IF 6.51, 药学小类I区) doi: 10.1016/j.ejmech.2019.02.067

15. Chen, Z.; Cen, X.; Yang, J.; Tang, X.; Cui, K.; Cheng, K.* “Structure-based discovery of a specific TLR1-TLR2 small molecule agonist from ZINC drug library database”. Chem. Comm. 2018, 54, 11411-11414 (IF 6.22, 大类1区) doi:10.1039/C8CC06618C

16. Cen, X.; Cheng, K.* “Ter-cell, a new target for hepatocellular carcinoma therapy”. ChemBioChem 2018, 19, 2254-2256. (IF 3.16, 药学3区) doi: 10.1002/cbic.201800410

17. Cen, X.; Liu, S.W.; Cheng, K.* “The Role of Toll-Like Receptor in Inflammation and Tumor Immunity”. Front. Pharmacol. 2018, 9, 878. (IF 5.81, 药学2区)doi: 10.3389/fphar.2018.00878

18. Bhattacharyya, S.*; Wang, W.; Qin, W.; Cheng, K.; Coulup, S.; Chavez, S.; Raparia, K.; De Almeida, L. M.; Stehlik, C.; Tamaki, Z.; Yin, H.*; Varga, J.* “TLR4-Dependent Fibroblast Activation Drives Persistent Organ Fibrosis in Skin and Lung”. JCI Insight 2018, 3, e98850. (IF 8.31)

19. Xu, Y.; Chen, S.J.; Cao, Y.; Zhou, P.Z.; Chen, Z.P.; Cheng, K.* “Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents”. Eur. J. Med. Chem. 2018, 154, 253-266. (IF 6.51, 药学小类I区)doi: 10.1016/j.ejmech.2018.05.033

20. Cai, S.Y.; Zhu, G.Z.; Cen, X.H.; Bi J.J.; Zhang, J.R.; Tang, X.S.; Chen, K.; Cheng, K. * “Synthesis, structure-activity relationships and preliminary mechanism study of N-benzylideneaniline derivatives as potential TLR2 inhibitors”. Bioorg. Med. Chem. 2018, 26, 2041-2050. (IF 3.64,医学/药学3区) doi: 10.1016/j.bmc.2018.03.001

21. Zhu, G.Z.; Xu, Y.; Cen, X.H.; Nandakumar, K.S.; Liu, S.W.*; Cheng, K.* “Targeting pattern-recognition receptors to discover new small molecule immune modulators”. Eur. J. Med. Chem. 2018, 154, 82-92. (IF 6.51, 药学小类I区)doi: 10.1016/j.ejmech.2017.12.026

22. Xu, Q.; Zhu, G.Z.; Li, J.;*and Cheng, K.;* “Development of Antibacterial Drugs by Targeting Toll-Like Receptors”, Curr. Top. Med. Chem. 2017, 17, 270-277. (IF 3.29, 医学/药学3区)doi: 10.2174/1568026616666160829161639

23. Cheng, K.; Gao, M.; Godfroy, J. I.; Brown, P. N.; Yin, H.; “Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists”, Sci. Adv. 2015, 1, e1400139. (Science新子刊,IF:14.13). doi: 10.1126/sciadv.1400139

24. Cheng, K.; Wang, X. H.; Zhang, S. T.; Yin, H.; “Discovery of Small Molecule Inhibitors of the TLR1-TLR2 Complex”, Angew. Chem. Int. Edit. 2012, 51, 12246-12249. [Cover Article] [C&EN] (IF: 15.33, 综合1区) doi:10.1002/anie.201204910

25. Cheng, K.; Wang, X. H.; Yin, H.; “Small Molecule Inhibitors of the TLR3/dsRNA Complex”, J. Am. Chem. Soc. 2011, 133, 3764-3767. (IF: 15.41, 综合1区) doi: 10.1021/ja111312h


专利

1. Yin, H.; Cheng, K. “2-(4-Aryl-1H-Imidazol-1-yl)Aniline Compounds”, Prov. Appl. 2014, 61/989,603. PCT Int. Appl. 2015, US2015/29780.

2. Yin, H.; Cheng, K. “Antagonists of the Toll-Like Receptor 1/2 Complex”, Prov. Appl. 2012, 61/676,992; PCT Int. Appl. 2013, US2013/52517; USA Appl. 2014, 14/417,676; EU Appl. 2015, 13826030.2; Patent No. US 9,517,993 B2, issued on December 13, 2016. (已授权,此项专利已经与企业合作进行临床前研究)

3. Yin, H.; Cheng, K. “Modulators of TLR3/dsRNA Complex and Uses Thereof”, Prov. Appl. 2011, 61/434,492; PCT Int. Appl. 2012, US2012/021207; USA Appl. 2013, 13/980,874; EU Appl. 2013, 12736857.9; Patent No. US 9,409,880 B2, issued on August 9, 2016. (已授权,licensed by Tocris Bioscience, UK)

4. “Antitumor activity of benzoic nitrogen mustard derivatives and their preparation”, Originator: Zhu, H. L.; Zeng, Q. Z.; Cheng, K.; Jiao Q. C.; Patent (China) 200910036290.4

5. 程魁,刘叔文,朱耿桢。1,4-二苯基-1H-咪唑和2,4-二苯基噻唑类衍生物及其制备方法和用途,国际发明专利申请号:PCT/CN2018/082243,2018年4月9日申请。

6. Kui CHENG, Shuwen LIU, Gengzhen ZHU. 1,4-DIPHENYL-1H-IMIDAZOLE AND 2,4-DIPHENYLTHIAZOLE DERIVATIVES AND PREPARATION METHOD THEREFOR AND USE THEREOF. Patent No. US 2021/0017189 A1, issued on January 22, 2021.

7. 程魁,许尧。一种咔唑β-氨基醇类衍生物及其制备方法和用途,专利授权号:ZL 2018 1 0122217.8,2018年2月7日申请,2020年8月14日授权。公告号:CN 109867662 B

8. 程魁,许尧。一种取代苯酚β-氨基醇类衍生物及其制备方法和用途,专利申请号:201810122219.7,2018年2月7日申请,2021年5月7日授权。公告号:CN 109867627 B

9. 程魁,陈之朋,刘叔文。2-硫脲基(脲基)噻吩-3-甲酸酯类衍生物及其用途,专利授权号:ZL 2018 1 1074103.7,2018年9月14日申请,2020年5月22日授权。公告号:CN 108976195 B

10. 程魁,毕静杰。N-(苯甲酰基)-L-半胱氨酸甲酯类衍生物及其制备方法和用途,专利授权号:ZL 2019 1 0395765.2,2019年5月13日申请,2020年9月4日授权。公告号:CN 110041239 B

11. 程魁,陈之朋,刘叔文。N-芳基-N'-(2-噻吩基)硫脲(脲)衍生物及其制备方法和用途, 专利申请号:ZL 202110405590.6,2021年4月5日申请.